# Adolescent Depression and Suicidality

## Introduction

Depression in adolescents is a leading cause of disability worldwide, and suicide is the second leading cause of death among individuals aged 10-24. Adolescent depression frequently presents differently from adult depression, often manifesting as **irritability** rather than sadness. Early identification and evidence-based treatment are essential, as untreated depression during this critical developmental period increases the risk of recurrence, substance use, academic failure, and completed suicide.

## Epidemiology

Lifetime prevalence of major depressive disorder (MDD) in adolescents: approximately **11-14%**. Female-to-male ratio increases to approximately 2:1 after puberty onset. Median age of onset: 14-15 years. Suicide rates among adolescents have increased significantly since 2007, with particular increases among females and minority youth.

## Clinical Presentation

### Differences from Adult Depression

**Irritability and anger** may be more prominent than sadness. Somatic complaints: headaches, stomachaches, fatigue. Academic decline and school refusal. Social withdrawal from peers or, conversely, increased conflict with family. Increased sensitivity to rejection.

### DSM-5 Criteria for MDD in Adolescents

Same criteria as adults, with the note that **irritable mood may substitute for depressed mood** in children and adolescents. Five or more symptoms for at least 2 weeks. Must include depressed/irritable mood or anhedonia. Duration criterion for dysthymia (persistent depressive disorder) is 1 year in youth vs. 2 years in adults.

![Comparison of depression presentations in adolescents versus adults](images/adolescent-vs-adult-depression.png)

## Assessment

### Clinical Interview

Interview the adolescent **alone** and with the parent/caregiver. Ask directly about suicidal ideation, self-harm, and access to lethal means. Assess psychosocial context: bullying, academic pressure, family conflict, identity development, social media use.

### Screening Tools

**Patient Health Questionnaire for Adolescents (PHQ-A)**. **Columbia Suicide Severity Rating Scale (C-SSRS)**. **Beck Depression Inventory-II (BDI-II)**, validated for ages 13+.

### Differential Diagnosis

Bipolar disorder (screen for manic/hypomanic episodes and family history) Substance use disorders. Medical conditions: hypothyroidism, anemia, infectious mononucleosis. ADHD and anxiety disorders (frequently comorbid)

## Suicide Risk Assessment in Adolescents

### Risk Factors

Prior suicide attempt (strongest predictor) Family history of suicide. Access to firearms or lethal means. LGBTQ+ identity (elevated risk due to minority stress, not identity itself) History of abuse or trauma. Cluster phenomena: exposure to peer or media suicide.

### Protective Factors

Strong family connectedness and parental monitoring. School engagement and sense of belonging. Cultural and religious beliefs that discourage suicide. Access to mental health care. Problem-solving and emotion regulation skills.

### Means Restriction

**Lethal means counseling** is an evidence-based suicide prevention strategy. Firearms should be removed from the home or secured with trigger locks and separate ammunition storage. Medication quantities should be limited; secure access to potentially lethal medications.

![Suicide risk and protective factors framework for adolescent assessment](images/adolescent-suicide-risk-framework.png)

## Treatment

### Psychotherapy

**CBT for adolescents** is first-line for mild to moderate depression. **Interpersonal psychotherapy for adolescents (IPT-A)**: focuses on role transitions, interpersonal disputes, and grief. Family-based interventions, particularly **Attachment-Based Family Therapy (ABFT)** for suicidal adolescents.

### Pharmacotherapy

| Medication | FDA Approval (Age) | Starting Dose | Target Dose | Key Evidence |
|-----------|-------------------|--------------|-------------|--------------|
| Fluoxetine | MDD age 8+ | 10 mg/day | 20-40 mg/day | TADS trial: fluoxetine + CBT superior to either alone |
| Escitalopram | MDD age 12+ | 5 mg/day | 10-20 mg/day | Positive RCTs in adolescents |
| Sertraline | Not FDA-approved for MDD (approved for OCD age 6+) | 25 mg/day | 50-200 mg/day | Mixed evidence for MDD; useful for comorbid anxiety |
| CBT + Fluoxetine | N/A | N/A | N/A | Best outcomes in TADS; combination is first-line for moderate-severe |

**Fluoxetine** is FDA-approved for MDD in children aged 8+ and is the first-line SSRI. **Escitalopram** is FDA-approved for adolescents aged 12+. The TADS study demonstrated that combined fluoxetine + CBT was superior to either alone. Start low and titrate slowly; monitor closely during the first 4-6 weeks.

### The Black Box Warning

FDA black box warning on antidepressants for increased suicidality in youth under 25. The warning led to decreased prescribing but a paradoxical increase in adolescent suicide rates. Clinical consensus: the **benefits of appropriately prescribed SSRIs outweigh the risks** for moderate to severe depression. Requires close follow-up: weekly for the first month, biweekly for the second month.

### Safety Planning

Collaborative development of a written **safety plan** with the adolescent and family. Identify warning signs, coping strategies, supportive contacts, and crisis resources. Restrict access to lethal means. Establish clear follow-up and crisis protocols.

![Stepped-care treatment model for adolescent depression](images/adolescent-depression-treatment-steps.png)

## Key Clinical Pearls

Always ask about suicidal ideation directly; asking does not increase risk. Irritability in an adolescent warrants depression screening, not just a behavioral intervention. Social media use exceeding 3 hours daily is associated with increased depression risk in adolescents. Non-suicidal self-injury (NSSI) is common in depressed adolescents and is an independent risk factor for future suicide attempts. Involve the family in treatment while respecting the adolescent's emerging autonomy and confidentiality needs.

## References

1. March JS, Silva S, Petrycki S, et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents with Depression Study (TADS). *JAMA*. 2004;292(7):807-820.
2. Brent DA, McMakin DL, Kennard BD, et al. Protecting adolescents from self-harm: a critical review of intervention studies. *J Am Acad Child Adolesc Psychiatry*. 2013;52(12):1260-1271.
3. Zuckerbrot RA, Cheung A, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice preparation, identification, assessment, and initial management. *Pediatrics*. 2018;141(3):e20174081.
4. Olfson M, Druss BG, Marcus SC. Trends in mental health care among children and adolescents. *N Engl J Med*. 2015;372(21):2029-2038.